Medicines showing this symbol are subject to additional monitoring. This will allow quick identification of new safety information. Please click here for more information.
- Active Ingredients
Product Documentation
-
View RMM (Hetronifly 10 mg/ml concentrate for solution for infusion)
Last updated on this site: 24 Nov 2025
New Product Launch 21/11/25.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintHetronifly 10 mg/ml concentrate for solution for infusion
Medicines showing this symbol are subject to additional monitoring. This will allow quick identification of new safety information. Please click here for more information.
- PL Number:
- 20075/1559
- MA Holder:
- Accord Healthcare Limited
- Product Classification:
-
POM
- Product Status:
- Active
Product Documentation
-
View Patient Information Leaflet (Hetronifly 10 mg/ml concentrate for solution for infusion)
Last updated on this site: 30 Jun 2026
To extend the therapeutic indication to include Oesophageal squamous cell carcinoma (OSCC)- HETRONIFLY in combination with fluoropyrimidine- and platinum based chemotherapy is indicated for the first-line treatment of adult patients with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma whose tumours express PD-L1 with a CPS greater than or equal to 5. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of SmPC and PIL have been updated. The updated RMP version (3.1) has also been included.
Variation approval date: 26/06/2026
PIL sections updated: Index, 1, 2, 3, 4, 5 and 6
View Summary of Product Characteristics (Hetronifly 10 mg/ml concentrate for solution for infusion)Last updated on this site: 30 Jun 2026
To extend the therapeutic indication to include Oesophageal squamous cell carcinoma (OSCC)- HETRONIFLY in combination with fluoropyrimidine- and platinum based chemotherapy is indicated for the first-line treatment of adult patients with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma whose tumours express PD-L1 with a CPS greater than or equal to 5. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of SmPC and PIL have been updated. The updated RMP version (3.1) has also been included.
Variation approval date: 26/06/2026
SmPC sections updated: 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 10
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaint
For any further assistance, please get in touch.